Maria de Jesus Perry
PhD (2003) in Pharmacy (Pharmaceutical Chemistry), Universidade de Lisboa
Assistant Professor, Pharmaceutical Chemistry and Organic Chemistry
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
My area of research in Medicinal Chemistry is focused in Drug Design. Areas of active interest include organic synthesis and identification of biologically active small molecules, prodrugs development, targeted drug delivery, drug metabolism and drug stability. In the recent years I have been involved in the development of hybrid drugs for resistant malignancies namely cancer and malaria.
Science communication activities are another complement that also gives me some rewarding.
Sousa A , Santos F, Gaspar MM, Calado S, Pereira JD, Mendes E, Francisco AP, Perry MJ. The selective cytotoxicity of new triazene compounds to human melanoma cells. Bioorg Med Chem 2017; 25:3900-3910.
Pinheiro R, Braga C, Bronze MR, Perry MJ, Moreira R, Brites D, Falcão AS. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference? ACS Chem Neurosci, 2017; 8: 50-59.
Oliveira R, Miranda D, Magalhães J, Capela R, Perry MJ, O’Neill PM, Moreira R. From Hybrid Compounds to Targeted Drug Delivery in Antimalarial Therapy. Bioorg & Med Chem 2015; 23: 5120-5130.
Rodrigues CA, Frade RF, Albuquerque IS, Perry MJ, Gut J, Machado M, Rosenthal PJ, Prudêncio M, Afonso CA, Moreira R. Targeting the Erythrocytic and Liver Stages of Malaria Parasites with s-Triazine-Based Hybrids. ChemMedChem 2015; 10: 883-890.
Pereira NAL, Monteiro A, Machado M, Gut J, Molins E, Perry MJ, Dourado J, Moreira R, Rosenthal PJ, Prudêncio M, Santos MMM. Enantiopure Indolizinoindolones with in vitro Activity against Blood- and Liver-Stage Malaria Parasites. ChemMedChem 2015; 12: 2080-2089